|
Invention relates to the field of genetic engineering and medicine. Claimed method of treating neurodegenerative diseases and Alzheimer's disease, including intranasal introduction to the subject of a therapeutically effective quantity of YB-1 protein, possessing an amino acid sequence of human SEQ ID NO:1 or rabbit SEQ ID NO:7 and/or its active fragment separately or in a composition, which additionally contains one or several agents, which enhance the intranasal delivery of the composition to the brain. |
|
Method of treating chronic limb ischemia experimentally Limb ischemia is simulated in a male Wistar rat anaesthetised with chloral hydrate in a dose of 250-300 mg/kg by the surgical removal of femoral, popliteal arteries and the front shin artery. That is followed by introducing a prepared mononuclear fraction of the autologous bone marrow in a dose of 4×106 cells in an amount of 200 mcl. The above is introduced into the ischemic limb from two points in an amount of 100 mcl each. One point is found directly under the femoral arch paravasally within the anatomical position of collaterals of the inner iliac artery and its branches. The other point is located in the calf muscle on an anteriolateral surface of the midleg. |
|
Method of extracting proteins from bone marrow cells Invention relates to biochemistry. Method includes extraction of bone marrow cells, their suspension, suspension filtration and centrifugation of filtrate. Sediments are subjected to homogenisation together with supernatant liquids. Then, content of centrifugal vials is filtered through polycaprolactam filters. Proteins of solution salted out by means of ammonium sulphate at heating to 60°C, settled for 12 h at temperature 4°C and centrifuged at 2000 rev/min for 5 min. 1% solution of trichloracetic acid is added to supernatant liquid, then sediment is also separated from solution by centrifugation at 2000 rev/min for 5 min. Obtained sediments are washed away with alcohol and ether and dried on watch glass 0.9% of sodium chloride solution is added to obtained powder, mixed thoroughly, then protein solution is subjected to dialysis with running water for 1-2 days and distilled water for 1 h. Solution is centrifuged at 2000 rev/min for 5 min, obtained sediments are washed away with alcohol and ether, dried on watch glass. |
|
|
Pharmaceutical composition contains a therapeutic amount of a sterile isolated chemotactic stem cell product, a stabilising amount of serum and a therapeutic agent for promoting the existing cardiomyocyte function in order to compensate the deprivation of the cardiomyocyte function caused by the cardiomyocyte death. |
|
Method of treating lower extremity ischemia Invention refers to medicine, namely to treating lower extremity ischemia. That is ensured by administering a suspension of mononuclear self-specific marrow cells through a microcatheter directly into the ischemic region after performing an angioplasty if a steno-occlusive involvement of peripheral arteries. |
|
Method for repairing long bone defects of critical size Group of inventions refers to medicine, namely to orthopaedics, and can be used for producing a transplant for long bone tissue repair. That is ensured by collecting bone marrow aspirate into lithium heparin test tubes, diluting with phosphate salt buffer, filtered through a filter with pore size 70 mcm and centrifuging for 10 min at 400 g. That is followed by inoculating flasks 150 cm2 with the produced mesenchymal stem cells (MSCs) at 1×106 cells/cm2, culturing at temperature 37°C and 5% CO2 in air, in the Dulbecco's Modified Eagle's medium containing glucose 1 g/l and less, with 10% embryo calve serum. The medium is changed every 3 days. Before preparing the transplant, the cells are removed from the substrate with 0.05% trypsin EDTA, washed and re-suspended. The cell suspension is applied on the matrix, incubated for 3 hours at temperature 37°C with rocking in a rotation shaker at 25 rpm. The matrix is filled with the DMEM medium with 10% bovine foetal serum, dexamethasone 10-7 M, β-glycerophosphate 10 mM, ascorbate-2-phosphate 0.05 mM, 1% streptomycin 100 mcg/ml or penicillin 100 units/ml. The MSCs are cultured for 28 days. What is also presented is a method for long bone tissue repair. |
|
|
Engineered mesenchymal stem cells and method for using them for treating tumours Invention refers to molecular biology and genetic engineering. What is declared is a genetically modified mesenchymal stem cell for the selective expression of cytotoxic protein containing exogenous nucleic acid comprising a region coding cytotoxic protein and functionally bound to a promoter or a combination of promoter/enhancer, wherein the promoter or the combination of promoter/enhancer cause the selective expression of cytotoxic protein, when the genetically modified mesenchymal stem cell closes the stromal tumour tissue. |
|
Method of treatment of subclinical mastitis in lactating cows Method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml. |
|
|
Method of treating age-related macular dystrophy Mesenchymal stem cells are introduced into superior and inferior alveolar processes within roots of teeth. Herewith, 500-600 thousand cells are introduced into the superior alveolar process within the root of incisors, 800 thousand - 1 million cells - into the root of canine teeth, 1 million - 1 million 200 thousand cells into the root of premolar and molar teeth. Besides, 500-700 thousand cells are introduced into the inferior alveolar process within the root of incisors, 800 thousand - 1 million cells - into the root of canine teeth, 1 million - 1 million 200 thousand cells into the root of premolar and molar teeth. The therapeutic course involves 5-7 introductions every 2-3 weeks. |
|
|
Invention relates to the field of medicine, namely to cell transplantology for the regeneration of a bone tissue in surgical treatment of destructive, degenerative-dystrophic, traumatic or congenital affections of the bone tissue. A biotransplant contains a mixture of autologous multipotent mesenchymal stromal cells, cultivated in standard conditions, and multipotent mesenchymal stromal cells, differentiated in the osteogenic direction, taken in a weight ratio of 1:1 and in quantity of 107 cells per 1 g of the weight of a matrix-carrier, which has in the basis of its structure a collagen-mineral complex, identical in the composition to natural bone material. A method of the biotransplant obtaining is based on the application of the culture medium AdvanceSTEMTM/Antibiotic/Antimycotic Solution 100x with an addition of 10% of autologous serum of the patient's blood. |
|
Method of antitumour immunotherapy Invention relates to medicine, namely to oncology, and can be applied for antitumour immunotherapy. For this purpose, dendritic cells (DC), obtained from a patient's skin, spleen, bone marrow, thymus, lymph nodes, umbilical blood or peripheral blood (autologous DC) are introduced to the patient, with DC being introduced to the patient step-by-step. At the first stage the introduction of mature allogenic DC, loaded with a tumourspecific antigen, maturation of which is realised ex vivo, is performed. At the second stage not less than 24 hours, but not more than 120 hours after the first stage the re-introduction of allogenc DC is realised simultaneously with the introduction of immature autologous DC in situ in a tumour, with the tumour being subjected to an ablation impact preliminarily or simultaneously with DC introduction. |
|
|
Method of comprehensive treatment of cows with postpartum endometritis Method of comprehensive treatment of cows with postpartum endometritis comprises repeated subcutaneous injection of preparation of general stimulating nonspecific therapy in conjunction with symptomatic and etiotropic preparations, and the preparation of general stimulating nonspecific therapy is used as tissue biostimulant from the spleen, which is administered subcutaneously five times with an interval between injections of 48÷72 hours with increasing doses of 30, 35, 40, 45 and 50 ml. |
|
|
Method of comprehensive treatment of mastitis in lactating cows Method comprises intracisternal administration of masticef at a dose of 5 ml with 24-hour intervals 2-4 times. The biogenic stimulator is used as a preparation obtained from pig spleen (BSS) by ultrasonic homogenisation, heating the homogenate, and its cooling, supernatant precipitation followed by removal of ballast proteins by centrifugation or ultrafiltration. The biogenic stimulator is administered subcutaneously in the upper third part of the neck in 1-3-5-7 days of treatment at a dose of 30-35-40-45 ml, respectively. |
|
|
What is applied is a stocking coating of an autogenous bone with a patient's platelet-rich plasma. Bone marrow aspirate from the patient's ilium and/or mesenchymal stromal cell autoculture prepared of the aspirate by culturing in vitro are injected under the coating layer into the autogenous bones. The autogenous bones are placed tightly in the bone defect to cover the defect area with adjacent soft tissues. |
|
Compositions improving infarction perfusion, and methods for recovering vascular involvement Group of inventions refers to medicine, and concerns a method for cardiac function recovery following acute myocardial infarction with infarction involvement, wherein the method involves introducing into an individual a non-swelling, recovered population of autogenous mononuclear cells enriched with CD34+ cells containing a subpopulation, at least 0.5×106 of high-active CD34+ cells expressing XCR-4 possessing CXCR-4 mediated chemotactic activity and shifting in response to SDF-1; using the pharmaceutical composition for preparing a therapeutic agent for the cardiac function recovery in the individual after acute myocardial infarction with an infarction inflammation, wherein the pharmaceutical composition contains the above recovered population of the autogenous mononuclear cells. |
|
Method of treating immune dysfunction, such as graft-versus-host or host-versus-graft disease Group of inventions refers to medicine, namely to transplantology, and may be used for treating graft-versus-host disease (GVHD). That is ensured by introducing pluripotent cells, other than embryo stem cells, embryo germ-line cells, germ-line cells into an individual. The cells may differentiate in one cell type of any of at least two embyo lines - endodermal, ectodermal and mesodermal. The cells express telomerase; they are allogenic for the individual and promote the negative immune response. The group of inventions also refers to the above cells which are grown and processed during 10 to 40 cycles of cell duplication in a culture, and then specific markers (oct-3/4, rex-1 and rox-1) are expressed. |
|
Invention refers to chemical-pharmaceutical industry, and represents an immunomodulator for treating chronic hepatitis, hepatic cancer, lymphatic sarcoma, chronic leukemia, and for improving the functions of liver and blood-forming organs, for enhancing the immunobiological body characteristics, prepared by mixing 1000 ml of an aqueous infusion of sandy everlasting blossom, pepper mint herb and chicory herb with 50 ml of bovine serum containing leukaemia oncovirus antibodies, 20 ml of wild rosemary infusion, 40 g of ascorbic acid, 2 g of sorbic acid, 0.2 g of folic acid until the ingredients are dissolved completely, with adding 60 g of liver powder, 30 g of lymphatic node powder, 30 g of young bovine spleen powder; the prepared solution is settled at room temperature for 24 hours, then kept at a boiling water bath for 30 minutes and cooled for 6-8 hours at room temperature; the settled solution is filtered, wherein the aqueous herbal solution is prepared by mixing equal proportions of the separately prepared aqueous infusions of 40 g of pepper mint herb in 1000 ml of water, 30 g of sandy everlasting blossom in 1000 ml of water and 30 g of chicory herb in 1000 ml of water, while the wild rosemary infusion is prepared by infusing 60 g of ground wild rosemary blossom in 1000 ml of 70% purified ethanol. |
|
|
Method to extract stem cells from bone marrow for intravascular introduction Method is proposed to extract stem cells, including whirling of heparinised bone marrow with hydroxyethyl starch at the ratio of source ingredients of 1:2 with speed of 700g for 15 min. in the closed system of three haematological containers connected to each other with tubes with subsequent removal of fat admixtures and plasma into the container No.1, transfer of the mononuclear fraction of bone marrow, a part of supernatant and erythrocytes adjoining the interface of two media into the container No.2. Sludged erythrocytes and bone fragments remain in the main container, whirling of the produced sample with the speed of 900g for 15 min. in the container No.2 to produce cell material for intravascular introduction, at the same time after the specified whirling a part of supernatant is removed into the container No.1 without unsealing of the system. |
|
|
Combination of blood and ceramic particles of biphasic calcium phosphates Group of inventions refers to medicine. A method for preparing a biomaterial, which provides bone tissue regeneration, contains biphasic calcium phosphate (BCP) in the form of granules homogeneously dispersed in a three-dimensional blood protein mesh or bone marrow protein mesh, including the following steps: (i) mixing biphasic calcium phosphate in the form of granules of 40 to 500 mcm with blood or bone marrow aspirate in ratio 10 to 90 wt % of BCP of blood or bone marrow volume, g/ml; (ii) adding at least one coagulant to the mixture prepared at the stage (I) in an amount adequate to cause blood or bone marrow coagulation. The biomaterial further contains one additive specified in polymers, ceramics particles, pharmaceutical compounds, natural or synthetic growth factors, biomarkers, contrast agents, tissue or cell preparations. The kit for implementing the method comprises (a) a device having an internal sterile container with BCP; (b) a sterile container with a coagulant. The biomaterial is used in vitro or ex vivo as a carrier for produced bone tissue, or for producing a bone graft. |
|
Three-component complex for cell therapy in ophthalmology Invention relates to medicine, in particular to ophthalmology, and can be applied for cell therapy in case of different ophthalmopathologies, accompanied by dystrophic and atrophic processes as well. Three-component complex for cell therapy contains mesenchymal stem cells, labeled by magnetic microparticles. Cells are translocated into biological or synthetic fine-pore material, which in its turn is strongly fastened with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multipolar reverse magnetisation. |
|
|
Method of treating optic nerve atrophy of different etiology Invention relates to medicine, in particular to ophthalmology, and can be used for treatment of optic nerve atrophy of different etiology. Tree-component complex is implanted to patient in such a way that it covers optic nerve, posterior short ciliary arteries and part of retrobulbar cellular tissue, without joining them. Three-component complex contains mesenchymal stem cells, labeled with magnetic microparticles. Cells are transposed into biological or synthetic fine-porous material, which is tightly connected with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multi-polar reversible magnetisation. |
|
|
Method of surgical treatment of progressing and complicated myopia Invention relates to medicine, in particular to ophthalmology, and can be used for surgical treatment of progressing and complicated myopia. As scleroplastic material implanted is three-component complex, which contains mesenchymal stem cells, labeled with magnetic microparticles. Cells are translocated into biological or synthetic fine-porous material, which is tightly connected with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multi-polar reversible magnetisation. |
|
|
Invention refers to medicine, and concerns a method for preparing a drug preparation of an immunomodulator for severe purulent-septic and autoimmune diseases on the basis of a peptide fraction recovered from mammalian spleen tissue or cells (particularly swine or cattle spleen). Substance of the invention: there are mixed biologically active substance - that is a peptide fraction recovered from mammalian spleen tissue or cells with a substance preventing protein molecule coagulation, and an antibiotic. Gelofusine is used as the substance preventing protein molecule coagulation. |
|
|
Method and composition for tissue regeneration using stem or marrow cells Invention refers to pharmaceutical industry, namely a blood polymer for the regeneration of injured tissue or defect osseous or chondral structures. The blood polymer for the regeneration of injured tissue or defect osseous or chondral structures containing: blood, blood plasma or thrombocyte concentrate, erythropoietin (EPO), stem cells or marrow cells, wherein the blood polymer is prepared by mixing the respective ingredients taken in the liquid state, and the polymerisation is ensured by a gelling material specified in calcium ions, thrombin, protamine, prothrombin, fibrin or the extra-cellular matrix ingredients of a biological nature. The method for the regeneration of injured tissue or defect osseous or chondral structures in an individual. |
|
|
Method of correcting immune disorders Invention relates to medicine, in particular to experimental surgery and pathophysiology and can be applied for correction of immune disorders. in order to model immune disorders complete aspleenisation is performed to rats of Vistar line. 1 ml of suspension of a day culture of allogenic mononuclear cells of bone marrow from healthy rats, containing 2.4×108 cells is introduced intraperitoneally in early postoperative period. |
|
Method of treating "dry" form of age-related macular degeneration Invention relates to medicine, in particular to ophthalmology, and can be applied for treatment of "dry" form of age-related macular degeneration. Three-component complex, which contains mesenchymal stem cells, labelled with magnetic micro particles, is introduced to patient extrasclerally in macular zone projection. Cells in this complex are transposed into biological or synthetic fine-pore material. This material is fast connected with polymeric magnetic material with induction of permanent magnetic field 1.5 mT, with multipolar reversible magnetisation. |
|
|
Method of treating schizophrenia Invention relates to medicine, namely to psychiatry, and concerns treating schizophrenia. That is ensured by administering a composite solution of cytokines which is prepared by arteriovenous perfusion of porcine spleen by physiological saline at a flow rate of 30-40 ml/min followed by sterilisation filtration and cryo-preservation. The cytokine solution is administered by inhalations in the form of a fine aerosol by a nebuliser in a dose of 10 ml/administration. Depending on the patient's initial state and the distinctions/severity of the disease for the first 3-5 days, the preparation is administered every 8 hours, then for 5-10 days - 1-2 times a day with a frequency of administration to be reduced to 1 time/3 days for 3 months with underlying total withdrawal of psychotropic agents. |
|
|
Bioimplant with multifunctional bioactive nanostructured coating Invention refers to medicine and veterinary science; it is used in transplantology, traumatology, surgery and oncology, and may be used to fill bone defects. What is described is a bioimplant which represents a donor bone deimmunised with chlorine-containing oxidants, a surface of which is covered with a multifunctional bioactive nanostructured coating (MBNC) of M-Ca-P-C-O-N or M-Ca-CON, wherein M is a metal specified in a group consisting of Si, Ti, Zr, Hf, Nb, Ta, and colonised by recipient's mesenchymal stem cells (MSC). |
|
Method for producing bioengineered construct for bone defect replacement Invention refers to medicine and veterinary science, namely to reconstructive surgery it aims at the applications in transplantation, traumatology, surgery, and oncology. What is described is a method for producing bioengineered constructs for bone defect replacement, which is based on a bone anatomically compatible with the replaced one which is deimmunised in 5-10% solution prepared of a dry mixture of sodium chlorite, sodium perchlorate, sodium chloride in a ratio of 7:2:1 and distilled water; it is coated with heterogeneous implantable gel and colonised with multipotent mesenchymal stromal cells recovered from the recipient's bone marrow using immunomagnetic separation technique. |
|
Method of treating experimental 3,4-benz(α)pyrene induced tumours in splenectomised animals Invention refers to medicine, namely to experimental studies in oncology and may be used for intensifying action of anti-cancer preparations. A method of treating experimental 3,4-benz(α)pyrene induced tumours in splenectomised animals involves experimental study of anti-cancer action on the animals with removed spleen of white outbread rat ground in physiologic saline 5 ml in the sterile environment on ice; the prepared fluid in a centrifugal test-tube is settled for 10 minutes; a supernatant is collected and divided on 2 equal portions; one portion is placed in the medium 199 and left in a fridge at t 4-6°C for 24 hours; another portion is washed for three times in sterile physiologic saline and centrifuged at 1.5 rpm for 5 minutes; the prepared deposit is diluted to the required splenocyte concentration in physiologic saline; the amount of the suspension is 1 ml per 100 g of animal's weight; the splenocyte concentration is 5-6·109/l; cyclophosphan dosage is 40 mg/kg in the 1st day, 48 mg/kg in the 3rd day, total dosage is 88 mg/kg; the splenocyte suspension with cyclophosphane is incubated at temperature 37°C for 40 minutes; the spleen cell elements incubated with a chemopreparation is double introduced intravenously every 24 hours. |
|
|
Method of treating "dry" form of age-related macular degeneration Invention relates to medicine, namely to ophthalmology, and can be used for treatment of "dry" form of age-related macular degeneration. For this purpose at preliminary stage, magnetic implant in form of flat rectangular plate is implanted intrasclerally in projection of macular area. 2 weeks after that, mesenchymal stem cells (MSC) of patient's own bone marrow, labelled with magnetic microparticles, are introduced to patient intravenously during 30-40 minutes. 2 hours before MSC introduction macular area of retina is irradiated by low-intensive laser irradiation with wavelength 632-633 nm, voltage 10 mW, diameter of laser irradiation spot is 4 mm, total time of irradiation is 5 minutes. |
|
|
Invention refers to medicine, namely neurology, and may be used for treating complications caused by herpetic meningoencephalitis. A therapeutic effect is ensured by the endolumbar introduction of 1000000 autologous mesenchymal stem cells followed by the intramuscular introduction of ribonucleic acid hydrolysate 100 mg in one injection daily in the therapeutic course of 30 days. |
|
|
Invention refers to medicine, particularly ophthalmology, and may be used for treating peripheral and central tapetoretinal dystrophies. That is ensured by 5-10 procedures of the parabulbar introduction of α-fetoprotein 34-75 mcg in isotonic solution 1-3 ml in each eye once in 1-4 days. It is followed by the sequential parabulbar and retrobulbar injections of equal proportions of a suspension containing 10 mln. autologous mononuclears recovered from bone marrow. Bone marrow is taken 1-1.5 hours before the introduction. |
|
|
Method of treating wet age-related macular degeneration of retina with using cell transplantation Invention refers to medicine, namely ophthalmology, and concerns treating wet age-related macular degeneration (AMD). That is ensured by the injections of Lucentis 0.5 mg once a month into vitreous body. It is followed by the parabulbar introduction of alpha-fetoprotein 0.0075 mg in the evening and glutathione-S-transferase 0.0000005 g in the morning in isotonic solution 1.5 ml. The introduction is performed into each eye daily to visualise retina with neovasculature surrounding macula. Then laser vascular coagulation follows without macula damaging. A suspension of autologous bone marrow mononuclears are transplanted parabulbarly and retrobulbarly close to macula. Mononuclear count makes 5-40 mln. The suspension is introduced in NCTF-135 1.5 ml. The introduction is performed 2-4 times every 2 months. |
|
|
Method of treating diffuse myocardial damage Invention refers to medicine, specifically cardiology and cardiosurgery, and may be used for treating diffuse myocardial damage. That is ensured by cell sampling of mononuclear fraction of bone marrow in number of 10 mln cells. The 5 mln cells are introduced by aortic puncture between a coronary artery mouth and a short-term clamping point in an ascending section to a junction to a common carotid artery. The rest 5 mln cells are introduced by two injections. The first 2.5 mln cells are introduced in an apex of the left ventricular myocardium, while the second 2.5 mln cells are introduced into a side wall of the left ventricular myocardium. |
|
|
Method of ulcerative colitis and crohn's disease therapy Invention concerns medicine, particularly gastoenterology, and concerns treating ulcerative colitis and Crohn's disease. That is ensured by the oral introduction of the probiotic Bifiform in dose 2-3 capcules. It is followed by the 4-5-fold introduction of mesenchymal stem cells in number 150-200 mil. cells in 0.5 to 1.5 ml into a mucous membrane of changed intestinal segments. Further, Bifiform is introduced in dose 1 capsule 3 times a day for 3 weeks. |
|
|
Method of treating osteochondropathy of hip joint Invention relates to medicine, in particular orthopaedics. A whirlbone is centred; four to ten wires of the diameter 2.0 mm from a subtrochanteric region into a femoral neck. It is followed by draining irrigation of the joint with furacilin and isotonic solution. A perforator is used to form four-five canals ended in an epiphysis which are used to introduce 2 to 3 ml of the content from a medullary cavity of shin bone. A width of the joint space is adjusted by distraction. |
|
Method of treating neurotpophic ulcers of extremities Invention refers to medicine. A method involves in the fact that autologous cell cultures of patient's fibroblasts enriched with multipotent mesenchymal stem cells (MMSCs) are once transplanted on a wound surface. A portion of the culture MMSCs makes 5 to 15%. The cells are applied on the wound dropwise and fixed on the tissue defect with the use of a fibrine carrier and protected with a bandage made of platelet-rich plasma. |
|
Method of treating solid malignant growths and their metastases Invention refers to medicine, namely to oncology, also can be used in treating patients with solid tumours. For this purpose, 1-2 days prior to the initiation of chemotherapeutic procedures, a preparation of marrow mesenchymal stem cells coated with perfluorocarbon nanoparticles produced by incubation in a medium containing a pharmaceutically acceptable aqueous perfluorocarbon nanoemulsion of a particle diameter 300 nm and less is introduced to a patient intravenously in dose 0.5-10·106 cell/kg. Then the chemotherapeutic procedures follow with underlying oxygenated gas mixture inhalations at normal or high pressure. |
|
|
Method of treating optic nerve by transplantation of autologic stem cells Method includes delivery of biological material into area of optic nerve by injection parabulbarly, as well as by means of two microdrainages through the incision of sclera into sub-Tenon's and suprachoroidal spaces of eye. As biological material used is autologic cell material in form of suspension of bone marrow mononuclears, which contains patient's stem cells on carrier solution in concentration from 100000 to 1000000 cells per ml of suspension. Introduction is performed in portions every 1-2 hours up to 10 times per day for each separate way of introduction. Parabulbarly 1 ml per injection is introduced. Through microdrainages in sub-Tenon's space introduced are 1-4 ml per injection, into suprachoroidal space - 0.1-0.3 ml per injection. |
|
|
Method and transplant for treatment of liver failure Inventions relate to medicine, namely to cell transplantology, and deal with method and transplant for treatment of liver failure. For this purpose autologous progenitor cells of bone marrow are isolated and cultivated in vitro. Also realised is sampling of autologous liver cells. After that, immobilisation of autologous liver cells and progenitor cells of bone marrow on carrier - biodegradable biocompatible three-dimensional matrix is performed. After that, transplantation of carrier with cells is performed by its introduction into mesentery of small intestine. Transplant includes biodegradable biocompatible three-dimensional porous matrix with pore size 2-500 mcm and total porosity 50-97%, ensuring total concentration of liver cells and progenitor bone marrow cells 2×106-15×106 cells per 1 cm3 of matrix and ratio of progenitor bone marrow cells to liver cells from 1:1 to 1:4. Total volume of matrix constitutes not less than 0.05 cm3, its smallest linear size being not less than 0.2 mm. |
|
Method and transplant for treatment of liver failure Group of inventions relates to medicine and can be applied for treatment of liver failure. Transplant includes three-dimensional biocompatible biodegradable porous matrix, which has total volume not less than 0.05 cm3 and the smallest linear size not less than 0.2 mm, pore size 2-500 mcm, total porosity 50-97%, and implanted on it allogenic progenitor cells of bone marrow and allogenic liver cells, concentration of liver and bone marrow cells being 2×106-15×106 cells per 1 cm3 of matrix and ratio of bone marrow cells to liver cells being from 1:1 to 1:4. In realisation of method of treating liver failure transplant is placed into mesentery of small intestine. |
|
Method and transplant for treatment of liver failure Group of inventions relates to medicine and can be applied for treatment of liver failure. Transplant includes heterogenic biocompatible biodegradable gel, which has total volume not less than 0.1 ml and the smallest linear size not less than 0.2 mm, pore size 30-500 mcm, total porosity 50-98%, implanted on it autologous progenitor cells of bone marrow after their cultivation in vitro and cultivated autologous liver cells, concentration of liver and bone marrow cells being 2×106-15×106 cells per of 1 cm3 of heterogeneous gel and ratio of bone marrow cells to liver cells being from 1:1 to 1:4. In method of treating liver failure transplant is placed into parenchyma of liver and/or mesentery of small intestine. |
|
Method and transplant for treatment of liver failure Group of inventions relates to medicine and can be applied for treatment of liver failure. Transplant for treatment of liver failure includes heterogenic biocompatible biodegradable gel, which has total volume not less than 0.1 ml and the smallest linear size not less than 0.2 mm, pore size 30-500 mcm, total porosity 50-98%, implanted on it autologous progenitor cells of bone marrow after their cultivation in vitro and cultivated autologous liver cells, concentration of liver and bone marrow cells being 2×106-15×106 cells per 1 cm3 of heterogeneous gel and ratio of bone marrow cells to liver cells being from 1:1 to 1:4. In realisation of method of treating liver failure transplant is placed into parenchyma of liver and/or mesentery of small intestine. |
|
Method of estimating anti-ergotypic response in experiment Invention relates to biology and medicine, namely to experimental models of immunologic states, and can be used for estimation of anti-ergotypic response to vaccination with polyclonally activated cells. For this purpose vaccination with splenocytes, activated by means of anti-CD3 antibodies and interleukin-2, by subcutaneous injections 1 time per week during 4 weeks. After that response of delayed-type hypersensitivity (DTH) is induced by introduction of activated splenocytes under aponeurosis of animal paw pad. Anti-ergotypic response is estimated by degree of DTH development. |
|
Method of treating recurrent nasopharynx cancer Invention refers to medicine, namely to oncology, and can be used for treating patients with recurrent nasopharynx cancer. The method involves administration of chemopreparations and gamma-ray teletherapy; the first therapeutic day involves intravenous drop infusion of an automyelosuspension ex temporae incubated with cisplatin at 50 mg/m2 with underlying excessive hydration and forced diuresis; 5-fluorouracil dissolved in normal saline 200 ml is infused the same day at 500 mg/m2. After one day of a pause, gamma-ray teletherapy is performed in a hyperfractionation mode taking into account a residual dose 1.5 Gy of single basic dose twice a day every 5 hours to at 5 o'clock to 65 isoGy of total basic dose. After one week of a pause, the second course of automyelochemotherapy with cisplatin at 100 mg/m2 with underlying excessive hydration and forced diuresis is performed; 5-fluorouracil 500 mg/m2, bleomycine 30 mg/m2 and adriamycin 35 mg/m2 are infused the same day. |
|
|
Method of intraosseus chemotherapy of spine tumors Invention relates to medicine, namely to oncology, and can be used in chemotherapy of spine tumors. Method includes a puncture of spinous process of affected by tumor vertebra with paravertebral component and introduction of cytotoxic drugs in single doses, incubated with 2.0 ml of aspirated from spongy substance of bone hemato-bone-marrow suspension for 30 minutes a temperature 37°C, into punctured zone of affected vertebra. Then the secondary intravertebral incubation of cytostatic with hemato-bone-marrow suspension is carried out in intraorgan way at natural body temperature, followed by slow penetration of cytostatic into paravertebral component. |
|
|
Method of treating injuries of tendon-ligament structures of animal extremities Invention relates to field of veterinary. Method includes detection, instrumental examination of injured place and treating impact on the region of injury. In carrying out aspiration of bone marrow from sternum of injured animal, preliminarily sternum localisation is detected by palpation. Local anesthesia is performed and in the course of it trepanopunctures of spongy substance from sternum bone are carried out with medical needle for bone marrow biopsy, provided with mandrin and lateral holes on its end, with 1.5-2 cm step to the depth of penetration into sternum bone up to 1 cm. Bone marrow is sampled in volume 250-500 ml. In realisation of each puncture, aspiration of bone marrow dose is performed with syringe, containing mixture of NaCl 0.9% solution and heparin, it is filtered and all doses of bone marrow are collected into sterile airtight plastic bag, which contains 43 ml of anticoagulant CPDA. After that, bone marrow is separated with isolation of mesenchymal stem cell concentrate by means of apparatus for cell separation Sepax S-100 with volume 20-50 ml. Under control of injured place with ultrasound devices and/or thermography, boundaries of place to be treated and points of cell material introduction are marked with a marker, after which it is injected into the mass of injured ligament or tendon. After introduction of stem cells, injured segment of extremity is immobilised. |
|
|
Invention refers to medicine, and concerns a bioengineered structure for bony defect closure and osteogenesis which represents a hybrid implant comprising a porous polytetrafluorethylene membrane with a M-Ca-P-C-O-N or M-Ca-C-O-N doped multifunction, biocompatible, non-resorbed coating MBNC, where M is a metal chosen from a line including Ti, Zr, Hf, Nb, Ta, with autogenous or allogenic stromal cells recovered from fatty tissue or bone marrow passed on the surface thereof. |
|
Group of inventions relates to pharmacology and medicine. Fin order to obtain medicine, which has tissue-specific activity, animal organs are subjected to freezing not later than after 2 hours after raw material collection at temperature not lower than 40°C, kept at temperature minus 20-22°C during not less than two months. To milled frozen raw material 5% solution of acetic acid is added, bringing suspension temperature to 60-70°C and extraction of peptides into solution is carried out with constant mixing during not less than 2 hours. Supernatant fluid is siphoned and filtered through tissue, after which purified extract is directed to tangential micro-filtering. Obtained filtrate is directed to solid-phase extraction. Chromatography is carried out and on output from columns fractions of solutions are collected. Fractions, which contain peptide components, are united and directed to vacuum-evaporating plant, after which obtained target product is lyophilised. |
Another patent 2551241.